https://doi.org/10.4081/gc.2021.9891
The role of association between the cholinergic precursor choline alphoscerate and sulodexide in vascular dementia
Submitted: 2 June 2021
Accepted: 12 January 2022
Published: 24 January 2022
Accepted: 12 January 2022
Abstract Views: 2075
PDF: 228
HTML: 76
HTML: 76
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Dementia is a syndrome of acquired intellectual deficit resulting in significant impairment of social or occupational functioning. Vascular dementia (VaD) is the second most common causes of dementia after Alzheimer’s disease, causing around 15% of cases. However, unlike Alzheimer’s disease an involvement of the cerebral cholinergic system in the pathophysiology of VaD has been hypothesized and there is no standard treatment. In the Vascular Dementia Italian Sulodexide Study (VA.D.I.S.S.) the positive results obtained with the sulodexide are worthy of note. In this study 40 elderly subjects with recent onset (less than 9 month) slight to moderate mental deterioration due to vascular origin were observed for nine months during oral treatment with sulodexide and choline alphoscerate with the aim of analyzing whether therapeutic effects can be enhanced. These preliminary results suggest that the additional therapy of choline alphoscerate with sulodexide represents a way to increase the beneficial effects of cholinergic therapies in the VaD and improve all the different examinate score: mini mental state evaluation (MMSE), basic activities of daily living (ADL), instrumental activities of daily living (IADL).
Hachinski VC, Lassen MA, Marshall J. Multiinfarct dementia. A cause of mental deterioration in elderly. Lancet 1974;2:207-10.
DOI: https://doi.org/10.1016/S0140-6736(74)91496-2
Jellinger KA. The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol 2007;113:349-88.
DOI: https://doi.org/10.1007/s00401-006-0185-2
Vintiers HV, Ellis WG, Zarow C, et al. Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol 2000;60:658-9.
Rockwood K, Gauthier S, Erkinjuntti T. Prevention and treatment of vascular dementia: Vascular Cognitive Impairment, London UK: Martin Duniz Ltd; 2002. pp. 587-95.
Parnetti L, Mari D, Abate G, et al. Vascular dementia Italian sulodexide study (VA.D.I.S.S.) clinical and biological results. Thrombosis Res 1997;87:225-33.
DOI: https://doi.org/10.1016/S0049-3848(97)00122-9
Romain GC. Vascular dementia may be the most common form of dementia in the elderly. J NeurOl Sci 2002;203:7-10.
DOI: https://doi.org/10.1016/S0022-510X(02)00252-6
Wiswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology 2009;72:368-74.
DOI: https://doi.org/10.1212/01.wnl.0000341271.90478.8e
Chui HC, Gonthier R. Natural history of vascular dementia. Alzheimer Dis Assoc Disord 1998;13:S124-30.
DOI: https://doi.org/10.1097/00002093-199912001-00017
Richard E, Moll van Charante EP, van Gool WA. Vascular risk factors as treatment target to prevent cognitive decline. J Alzheimers Dis 2012;32:733-40.
DOI: https://doi.org/10.3233/JAD-2012-120772
Roman CG. Vascular dementia: distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc 2003;51:S296-304.
DOI: https://doi.org/10.1046/j.1532-5415.5155.x
Kalaria RN, Erkinjuntti T. Small vessel disease and subcortical vascular dementia. J Clin Neurol 2006;2:1-11;
DOI: https://doi.org/10.3988/jcn.2006.2.1.1
Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689-701.
DOI: https://doi.org/10.1016/S1474-4422(10)70104-6
Venkat P, Chopp M, Chen J. Models and mechanism of vascular dementia. Exp Neurol 2015;272:97-108.
DOI: https://doi.org/10.1016/j.expneurol.2015.05.006
Amenta F, Tayebati SK. Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. Curr Med Chem 2008;15:488-98.
DOI: https://doi.org/10.2174/092986708783503203
Parnetti L, Mignini F, Tomassoni D, et al. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or nedle for re-evaluation? J Neurol Sci 2007;257:264-9.
DOI: https://doi.org/10.1016/j.jns.2007.01.043
Vintiers HV, Ellis WG, Zarow C, et al. Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol 2000;60:658-9.
DOI: https://doi.org/10.1093/jnen/60.6.658-a
Court JA, Perry EK, Kalaria KN. Neurotransmitter control of the cerebral vasculature and abnormalities in vascular dementia: vascular cognitive impairment. London UK: Martin Duniz Ltd; 2002. pp.167-85.
Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline containing phospholipid with a still interesting profile as cognition enhancing agent. Curr Alzheimer Res 2013;10:1070-9.
DOI: https://doi.org/10.2174/15672050113106660173
Bartus RT, Dean RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-17.
DOI: https://doi.org/10.1126/science.7046051
Parnetti L. Amenta F, Gallai F. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mechan Ageing Develop 2001;122:2041-55.
DOI: https://doi.org/10.1016/S0047-6374(01)00312-8
Di Perri R, Coppola G, Ambrosio LA, et al. A multicentre trial to evaluate the efficacy and tollerability of glycerylphosphoryl-choline versus cytidine diphosphocholine in patients with vascular dementia. J Int Med Res 1991;19:330-41.
DOI: https://doi.org/10.1177/030006059101900406
Abbiati G, Fossati T, Lachmann G, et al. Absorption, tissue distribution and excretion of radiolabeled compounds in rats after administration of (14C)-L-alpha-glyceryl-phosphorylcholine. Eur J Drug Metab Pharmacokinet 1993;18:173-80.
DOI: https://doi.org/10.1007/BF03188793
Vezzetti V, Bettini R. Valutazione clinica e strumentale dell’effetto della colina alfoscerato sul decadimento cerebrale.
Presse Med 1992;5:141-4.Erkinjuntti T, Romàn GC, Gauthier S. et al. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 2004;35:1010-17.
DOI: https://doi.org/10.1161/01.STR.0000120731.88236.33
Amenta F, Carotenuto A, Fasanaro G, et al. Studio sull’effetto dell’associazione tra l’inibitore delle colinesterasi donepezil e il precursore colinergico colina alfoscerato sui sintomi della malattia di Alzheimer con danno vascolare associato (ASCOMALVA). Primi risultati.
Giorn Ital Geriatr 2011;LIX: 89-98.Barkhof F. Guidelines for brain imaging in vascular dementia clinical trials. Int Psychogeriatr 2003;1:273-6.
DOI: https://doi.org/10.1017/S1041610203009323
Mattana P, Mannello F, Ferrari P, et al. Vascular pathologies and inflammation: the antinflammatory properties of sulodexide. J Vasc Endovasc 2012;19:1-7.
Roman GC, Tatemichi TK, Erkinjutti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology 1993;43:250-60.
DOI: https://doi.org/10.1212/WNL.43.2.250
Chui HC, Victoroff JI, Margolin D, et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology 1992;428:473-80.
DOI: https://doi.org/10.1212/WNL.42.3.473
How to Cite
Di Salvo, A. (2022). The role of association between the cholinergic precursor choline alphoscerate and sulodexide in vascular dementia. Geriatric Care, 7(3). https://doi.org/10.4081/gc.2021.9891
Copyright (c) 2021 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.